Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: abiomed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $235.00 → $380.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/2/2022 | $355.00 → $388.00 | Buy → Hold | Deutsche Bank |
| 10/13/2022 | $300.00 | Buy | Mizuho |
| 4/6/2022 | $330.00 | Peer Perform | Wolfe Research |
| 2/4/2022 | $292.00 → $275.00 | Underweight | Morgan Stanley |
| 2/4/2022 | $345.00 → $325.00 | Market Perform | SVB Leerink |
| 1/7/2022 | $269.00 → $292.00 | Underweight | Morgan Stanley |
| 8/6/2021 | $335.00 → $375.00 | Market Perform | SVB Leerink |
| 7/20/2021 | $355.00 → $335.00 | Market Perform | SVB Leerink |
15-12G - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SC 13G - ABIOMED INC (0000815094) (Subject)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SC 13G - ABIOMED INC (0000815094) (Subject)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SC 13G - ABIOMED INC (0000815094) (Subject)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion
Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. ("Offeror"), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the "Offer") to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ:ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. The Offer, which was previously scheduled to expire at 11:59 p.m., New York City time, on December 13, 2022, has been extende
Abiomed (NASDAQ:ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed's newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005137/en/Impella RP Flex with SmartAssist Illustration (Graphic: Business Wire) Impell
CHELMSFORD, Mass., Nov. 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Tina S. Nova, Ph.D. and Dorothy E. Puhy have been nominated for election to its Board of Directors at the Company's 2023 Annual General Meeting. They will join as non-voting observers of the Company's Board of Directors with immediate effect. "We are fortunate to have candidates of the caliber of Tina and Dorothy for Azenta's Board," said Steve Schwartz, President and CEO. "They will bring tremendous life sciences experience to our Board and are proven value-creators in the space. Their perspectives will be invaluable as Azenta continues to expand and evolve as a leading life sciences company." J
ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa
Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil
Abiomed (NASDAQ:ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA's highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular (IJ) vein, which enables patient mobility, and has dual-sensor technology designed to optimize patient management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005234/en/Impella RP Flex with SmartAssist (Photo: Business Wire) The Impella RP platform includes the world's smallest percutaneous right heart mechani
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support Abiomed (NASDAQ:ABMD) announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients. Data from a subgroup analysis of 93 non-Caucasian high-risk PCI patients enrolled in the PROTECT II Randomized Controlled Trial (RCT) finds those who were treated with Abiomed's Impella heart pump had significantly improved clinical outcomes compared to those who were treated with the intra-aortic balloon pump (
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
Succeeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed's MedTech Conference 2022, which is taking place through Oct. 26 at the Boston Convention and Exhibition Center. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and will assume the role on January 1, 2023. This press release features multimedia. View the full release here: https
Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/Dr. Paula A. Johnson joins the Abiomed Board of Directors (Photo: Business Wire) "Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women," said Michae
Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt
S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI above or near 70. Novartis AG (NYSE:NVS) Novartis AG (NYSE:NVS) announced detailed results from the pivotal Phase 3 APPLY-PNH trial. The company’s stock has a 52-week high of $94.26 . RSI Value: 71.29 NVS Price Action: Shares of Novartis rose 0.4% to settle at $91.21 on Tuesday, and gained 0.4% in the pre-market trading session on Wednesday. Novo Nordisk A/S (NYSE:NVO) Novo Nordiskwill roll out its obesity treatment, Wegovy (semaglutide), in Europe in 2023 to ensure it has enough
Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. ("Offeror"), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the "Offer") to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ:ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. The Offer, which was previously scheduled to expire at 11:59 p.m., New York City time, on December 13, 2022, has been extended
Abiomed (NASDAQ:ABMD) has outperformed the market over the past 10 years by 29.45% on an annualized basis producing an average annual return of 40.14%. Currently, Abiomed has a market capitalization of $17.18 billion. Buying $100 In ABMD: If an investor had bought $100 of ABMD stock 10 years ago, it would be worth $2,754.63 today based on a price of $380.96 for ABMD at the time of writing. Abiomed's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and rev
- Reuters
Horizon Therapeutics Plc (NASDAQ:HZNP) confirmed it's engaged in preliminary talks with Amgen Inc (NASDAQ:AMGN), Janssen Global Service, and Sanofi SA SNY on potential takeover offers for the company. SVB Leerink projects 2023 revenue of $4.0 billion, adj operating income of $1.6 billion, and EPS of $5.51. Assuming no COGS nor R&D synergies but "fully synergized" SG&A of 21%, the company's theoretical 2023 fully synergized operating margin would be 54%, and adj EPS would be $7.79. If an acquirer were to pay a low-mid teens (13-15x) multiple of SVB's estimate of fully-synergized adj EPS, it could yield a potential acquisition price of $101-117/share. Valuation could be higher if an
Abiomed (NASDAQ:ABMD) has outperformed the market over the past 15 years by 18.87% on an annualized basis producing an average annual return of 25.88%. Currently, Abiomed has a market capitalization of $17.04 billion. Buying $1000 In ABMD: If an investor had bought $1000 of ABMD stock 15 years ago, it would be worth $31,567.25 today based on a price of $377.86 for ABMD at the time of writing. Abiomed's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and
Abiomed's (NASDAQ:ABMD) short percent of float has risen 6.62% since its last report. The company recently reported that it has 2.08 million shares sold short, which is 5.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
4 - ABIOMED INC (0000815094) (Issuer)
Morgan Stanley upgraded Abiomed from Underweight to Equal-Weight and set a new price target of $380.00 from $235.00 previously
Deutsche Bank downgraded Abiomed from Buy to Hold and set a new price target of $388.00 from $355.00 previously
Mizuho initiated coverage of Abiomed with a rating of Buy and set a new price target of $300.00
Wolfe Research initiated coverage of Abiomed with a rating of Peer Perform and set a new price target of $330.00
Morgan Stanley reiterated coverage of Abiomed with a rating of Underweight and set a new price target of $275.00 from $292.00 previously
SVB Leerink reiterated coverage of Abiomed with a rating of Market Perform and set a new price target of $325.00 from $345.00 previously
Morgan Stanley reiterated coverage of Abiomed with a rating of Underweight and set a new price target of $292.00 from $269.00 previously
SVB Leerink reiterated coverage of Abiomed with a rating of Market Perform and set a new price target of $375.00 from $335.00 previously
SVB Leerink reiterated coverage of Abiomed with a rating of Market Perform and set a new price target of $335.00 from $355.00 previously
Deutsche Bank initiated coverage of Abiomed with a rating of Buy and set a new price target of $360.00
ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa
Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil
Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The repla
ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. First Quarter 2023 Financial Highlights: Revenue of $277 million, an increase of 10%, or 12% in constant currency, compared to $253 million in the same period of the prior fiscal year. Worldwide product revenue of $264 million, an increase of 10%, or 12% in constant currency, compared to $241 million in the same period of the prior fiscal year. U.S. product revenue of $216 million, an increase of 9% compared to $197 million in the same period of the prior fiscal year due to a 6% increase in patient utilization. Out
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Thursday, August 4, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/551353819 or dial (888) 330-2413 the international number is (240) 789-2721 conference ID 83972. A replay of this conference call will be available until Thursday, August 11, 2022. The replay p
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summary and operational highlights: Revenue for the quarter totaled $270 million, an increase of 12% compared to $241 million during the same period of the prior fiscal year. In constant currency*, revenue increased 13% compared to the same period of the prior fiscal year. Full year revenue totaled $1.032 billion, compared to $848 million during the same period of the prior fiscal year. Full year revenue increased 22% on a repo
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, April 28, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (844) 200-6205; the international number is (929) 526-1599 access code 660077. A replay of this conference call will be available until Thursday, May 5, 2022. The repl
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, February 3, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (844) 200-6205; the international number is (929) 526-1599 access code 898485. A replay of this conference call will be available until Thursday, February 10, 2022.
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, October 28, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ET October 28, 2021 through
Abiomed (NASDAQ:ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005259/en/ Annually, more than one million patients are admitted to hospitals in the United States with ADHF. Despite available pharmaceutical treat